1 / 13

NON-INVASIVE EARLY SKIN CANCER DIAGNOSTIC SYSTEM

NON-INVASIVE EARLY SKIN CANCER DIAGNOSTIC SYSTEM. PULSE IMAGING, Inc. Company Overview. A World Without Skin Biopsies. 11/12/08. Problem. What if there is a skin cancer diagnostic technique that is painless, more accurate, less expensive, and quick? Early cancer detection critical

Olivia
Télécharger la présentation

NON-INVASIVE EARLY SKIN CANCER DIAGNOSTIC SYSTEM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NON-INVASIVE EARLY SKIN CANCER DIAGNOSTIC SYSTEM PULSE IMAGING, Inc. Company Overview A World Without Skin Biopsies 11/12/08

  2. Problem • What if there is a skin cancer diagnostic technique that is painless, more accurate, less expensive, and quick? • Early cancer detection critical • Current testing can be time-consuming, expensive, and uncomfortable • Currently dermatologists do multiple biopsies to detect a single case of melanoma • Lack of accurate instruments

  3. Background Short Pulse Laser Based Optical Tomography System world’s first fully software-controlled, desktop-size ultra-short pulse laser system providing high spatial and temporal resolution displays soft tissue contrast at cellular level Preliminary proof of concept demonstrated in animal model Provisional Patent (April 2006); Full patent filed (March 2007)

  4. Solution • Non-invasive Real-time Cancer Diagnostics • Less expensive • Eliminate unnecessary costly biopsies • Comfortable • Transportable compared to other imaging techniques • High sensitivity, specificity, and resolution • Fast image turnaround for patients • Reduce the probability of missing lesions especially in the margins compared to biopsies

  5. Resources and Capabilities Leverages existing Florida Tech’s human capital and infrastructure Development partnership with Raydiance Inc. Intellectual Property and Business Transactional capabilities through FIT Tech Transfer Office Design and prototyping capabilities Volume Production Concept Platform Developer Platform Production Version

  6. Paradigm Shifts • Discovery at university • Preliminary technology development completed • Design factors leading to several generation systems • Clinical trials for next generation system • Regulatory approval from FDA • Manufacture and ship systems to customers

  7. Market and Competition • Market size and Growth rate • More than 10 million skin biopsies are performed annually in US- by far the most common biopsy • Medical imaging market worth about $15B in 2006; app. 50% of the revenues garnered by the core modalities MRI, CT, x-ray, ultrasound • App. double digit market growth over the next five years • Medical expenditure for melanoma is $2.5B • Competitive Technologies • Biopsy vs Imaging Diagnostics such as MRI • Optical Coherence Tomography (OCT)

  8. Competition

  9. Sales and Distribution Target Distribution Partners or Customers Shands Healthcare Orlando Regional Healthcare Kaiser Permanente Mayo Clinic Sloan Kettering • Research Institutes • Research Hospital • Radiologists • PULSE IMAGING sales in year 5 • 200 systems • $300,000 per unit • 40% per year growth

  10. Management Team • CEO - TBA • Dr. Kunal Mitra - CTO; Responsible for overall product design and development • Robert Merrill - Florida Tech Tech Transfer Office • Ari Schuler - Raydiance Inc. (A DFJ Company); Commercialization partner • Dr. Carolyn Fausnaugh - Florida Tech School of Business; Responsible for market research • Dr. Grace – Florida Tech Biology Department; Responsible for animal studies • Regulatory Consultant - TBA

  11. Financial Forecast

  12. Use of Proceeds • Funding • Initial investment - $1 million • First year (2009) • Uses: • Prototype development for animal studies • Regulatory data development cost • Completion of clinical trials through partnership • Working investment capital

  13. Summary • “A World Without Skin Biopsies” • Conducting animal studies for safety and efficacy • Product development partnership in place • Patent application filed (2007) • Need for initial investment of $1 million Kunal Mitra, Ph.D. ProfessorMechanical and Aerospace Engineering DepartmentDirector- Biomedical Engineering ProgramFlorida Institute of Technology Phone: (321) 674 7131 Email: kmitra@fit.edu

More Related